House votes down right-to-try bill

The United States House of Representatives
The rejected legislation would have stripped the FDA of certain powers. (Lawrence Jackson/Public domain)

The House of Representatives has rejected a bill that would have cut the FDA out of the process for clearing terminally ill patients to access experimental medicine. House Democrats voted overwhelmingly against the law, resulting in it falling just short of the required two-thirds majority.

If passed, the bill would have enabled terminally ill patients to access unapproved drugs if a doctor and the manufacturer of the medicine agreed. Today, patients must get the clearance of a doctor, the manufacturer and the FDA. The rejected legislation would have stripped the FDA of the power to stop patients accessing medicines and limited its role to the receipt of safety reports.

Given the FDA approves almost all requests to access unapproved medicines, it is questionable how big an effect the law would have on the treatment options of terminally ill patients. But the proposal nonetheless provoked strong reactions in the House and beyond.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Some Republicans were accompanied to the debate about the bill by patients with terminal diseases, the AP reports, or cited messages from constituents affected by the law. A patient with amyotrophic lateral sclerosis said a vote against the legislation “is essentially a vote to kill me.”

Those strong messages and the support of the White House failed to sway 138 Democrats and two Republicans. Objections to the bill were underpinned by the belief that it would have little effect on access to medicines but would render patients vulnerable to exploitation by unscrupulous doctors and drugmakers, who would have total control if the FDA was cut out of the process.

The vote means that view, which is held by many patient and research groups, has won out for now. But House Republicans plan to return to the topic. As the Senate has already passed a similar bill, proponents of right-to-try could push legislation through under rules that would only require them to get a majority. This week’s vote suggests the bill would comfortably clear that lower bar.  

Suggested Articles

J&J's DePuy Synthes division has launched a new fixation system to expand treatment options for patients with frail bones in the neck and upper back.

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Tokyo-based Heartseed has raised 2.8 billion yen, or about $26 million U.S., to help develop its stem cell-based treatment for heart failure.